AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

@article{Liu2013ARVA,
  title={AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.},
  author={Gang Liu and Cynthia C T Sprenger and Shihua Sun and Kathryn Soriano Epilepsia and Kathleen Haugk and Xiaotun Zhang and Ilsa M. Coleman and Peter S. Nelson and Stephen R. Plymate},
  journal={Neoplasia},
  year={2013},
  volume={15 9},
  pages={
          1009-17
        }
}
Androgen deprivation therapy remains the primary treatment modality for patients with metastatic prostate cancer but is uniformly marked by progression to castration-resistant prostate cancer (CRPC) after a period of regression. Continued activation of androgen receptor (AR) signaling is attributed as one of the most important mechanisms underlying failure of therapy. Recently, the discovery of constitutively active AR splice variants (AR-Vs) adds more credence to this idea. Expression of AR-Vs… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

Mouse models of prostate cancer: picking the best model for the question

Magdalena M. Grabowska, David J. DeGraff, +4 authors Robert J. Matusik
  • Cancer and Metastasis Reviews
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Darwinian Selection in Prostate Cancer and Medical Treatment

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting Splicing in Prostate Cancer

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND